Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Quote. Delayed Nasdaq - 10/30 04:00:00 pm
58.15 USD   -0.65%
10/29GLOBAL MARKETS LIVE: Big names today
10/29GILEAD SCIENCES : Announces Fourth Quarter 2020 Dividend
AQ
10/29GILEAD SCIENCES : Announces Third Quarter 2020 Financial Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead to pay $97 million to settle U.S. kickback probe

share with twitter share with LinkedIn share with facebook
09/23/2020 | 11:11pm EDT
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California

Gilead Sciences Inc has agreed to pay $97 million to resolve U.S. government claims it used a purportedly independent charity to pay illegal kickbacks to cover Medicare patients' out-of-pocket costs for its pulmonary arterial hypertension drug Letairis.

The U.S. Department of Justice said on Wednesday the settlement resolves allegations that Gilead improperly used the Caring Voice Coalition as a conduit to cover thousands of patients' co-payment obligations.

Gilead's actions enabled the Foster City, California-based drugmaker to boost revenue, ran from June 2007 to December 2010, and violated the federal False Claims Act, the department said.

That law prohibits drugmakers from offering anything of value to induce Medicare patients to buy their drugs.

"Gilead used data from CVC that it knew it should not have, and effectively set up a proprietary fund within CVC to cover the co-pays of just its own drug," U.S. Attorney Andrew Lelling in Boston said in a statement.

He said such conduct undermines Medicare's co-pay structure, which Congress meant to prevent against inflated drug prices.

Drugmakers cannot subsidize co-payments for older Americans enrolled in Medicare, but may donate to independent non-profits that provide such assistance.

In a statement, Gilead said it addressed concerns raised by the government, and does not believe it violated the law. It also said there was no allegation that patients who received medication did not need it.

Gilead's settlement resulted from an industrywide probe led by Lelling's office into drugmakers' support for so-called patient assistance charities.

Eleven drug companies including Novartis AG, Pfizer Inc and United Therapeutics Corp have reached more than $1 billion of settlements with the government. Four foundations and a pharmacy have also settled.

By Jonathan Stempel


Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. -0.65% 58.15 Delayed Quote.-10.51%
NOVARTIS AG 0.53% 71.49 Delayed Quote.-22.21%
PFIZER INC. 0.57% 35.48 Delayed Quote.-9.44%
PFIZER LIMITED -0.93% 4985 End-of-day quote.18.01%
UNITED THERAPEUTICS CORPORATION 3.06% 134.23 Delayed Quote.52.40%
share with twitter share with LinkedIn share with facebook
All news about GILEAD SCIENCES, INC.
10/29GLOBAL MARKETS LIVE: Big names today
10/29GILEAD SCIENCES : Announces Fourth Quarter 2020 Dividend
AQ
10/29GILEAD SCIENCES : Announces Third Quarter 2020 Financial Results
AQ
10/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/29GILEAD SCIENCES : cuts 2020 sales outlook as COVID-19 drug remdesivir falls shor..
RE
10/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/28Gilead Quarterly Revenue Rises on Remdesivir Sales -- Update
DJ
10/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2020 23 690 M - -
Net income 2020 424 M - -
Net Debt 2020 19 768 M - -
P/E ratio 2020 107x
Yield 2020 4,63%
Capitalization 72 904 M 72 904 M -
EV / Sales 2020 3,91x
EV / Sales 2021 3,66x
Nbr of Employees 11 800
Free-Float 99,7%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 74,21 $
Last Close Price 58,15 $
Spread / Highest target 80,6%
Spread / Average Target 27,6%
Spread / Lowest Target -0,26%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-10.51%72 904
REGENERON PHARMACEUTICALS44.76%57 199
VERTEX PHARMACEUTICALS-4.84%54 210
WUXI APPTEC CO., LTD.71.31%40 863
BEIGENE, LTD.78.89%26 872
GENMAB A/S43.71%21 783